Most Read Articles
Roshini Claire Anthony, 3 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
04 Jan 2019
Obstructive sleep apnoea may increase the risk of male-pattern baldness in men with a family history of hair loss, and this association appears to be mediated by low serum transferrin saturation levels related to hypoxia, a study suggests.
2 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Thiazides, potassium citrate improve health-related QOL of patients with urolithiasis

16 Dec 2018

Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.

“These findings may be useful when counseling patients regarding the initiation of potassium citrate or thiazides for medical management of nephrolithiasis,” the authors said.

A total of 1,511 patients (787 males) were included in the study, of which 279 were on potassium citrate and 238 on thiazides. HRQOL in each domain was higher among patients treated with potassium citrate compared to those not treated with the said therapy (p<0.001). HRQOL was also higher among patients who received thiazides vs those who did not receive the said medication (p<0.01 for all).

Nausea, stomach upset or cramps (odds ratio [OR], 0.57; p<0.001) were less commonly reported among patients prescribed potassium citrate vs those not prescribed the said therapy. Moreover, patients who received thiazides were less likely to report fatigue (OR, 0.63; p=0.004) or reduced sexual interest and/or activity (OR, 0.64; p=0.005) compared to those who did not take the said treatment.

The authors obtained cross-sectional data on stone-forming enrolees in the North America Stone Quality of Life Consortium. They compared HRQOL between patients treated and not treated with potassium citrate or thiazide-type diuretics using the WISQOL questionnaire.

In addition, the authors compared the likelihood of gastrointestinal complaints between patients prescribed and not prescribed potassium citrate, as well as the likelihood of fatigue and sexual complaints in those prescribed and not prescribed thiazides.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
04 Jan 2019
Obstructive sleep apnoea may increase the risk of male-pattern baldness in men with a family history of hair loss, and this association appears to be mediated by low serum transferrin saturation levels related to hypoxia, a study suggests.
2 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.